Immunome, Inc.
Immunome, Inc. (IMNM) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMNM · as of Jun 8, 2026
Key Statistics
Explore Immunome, Inc. Data
imnm stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 13 · Buy rate: 100.0%
The IMNM analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month price target is $36.33, representing +95.22% upside from the current price of $18.61.
Competitors & Peers
imnm competitorsIMNM
ABCL
BHVN
CLDX
MAZE
NTLAStock Performance
Full HistoryAbout Immunome, Inc.
Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncolo…
what is immunome, inc. · imnm stock overview · immunome, inc. company profile · who is immunome, inc. ceo · imnm NASDAQ · immunome, inc. headquarters · immunome, inc. business segments
About Stock Overview & Key Data
Immunome, Inc. (IMNM) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 2, 2020. As of the latest trading session, IMNM stock price is $18.61, with a market capitalization of $1.8B. The stock has returned +100.43% over the past 12 months and -13.50% year-to-date.
According to 13 Wall Street analysts, the consensus rating for Immunome, Inc. stock is Buy, with an average 12-month price target of $36.33. In fiscal year 2025, Immunome, Inc. reported revenue of $6.9M and net income of -$212.4M. For detailed data — including Immunome, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Immunome, Inc. (IMNM) stock price is $18.61. The stock is traded on NASDAQ under the ticker symbol IMNM. The 52-week range is $7.96 – $27.65.